A meeting to be held in Newry, Maine, focusing on the latest developments and impact of Radionuclide Theranostics in management of patients with cancer. The meeting will promote formal and informal interactions and collaborations between an expert group of speakers including, scientists, physicians and discussants across basic and clinical translational science from academia, private practice and industry. The scientific goal of this meeting will be to address the challenges of radionuclide theranostics and encourage significant new science in the field of cancer. This meeting comes at a pivotal time when precision oncology using radionuclide-based imaging and therapy is at a tipping point of innovation and undergoing a fundamental transformation and unprecedented growth to offer more accurate diagnostics and personalized and effective antitumoral therapies than ever before.

Experts from the neuroendocrine cancer community who will be discussion leaders and guest presenters include:

• Joseph Dillon (University of Iowa, USA)
• Ken Herrmann (University of Duisburg-Essen, Germany)
• Ebrahim Delpassand (RadioMedix, USA)
• Andrew Bellizzi (University of Iowa, USA)
•  Kjell Oberg (Uppsala University, Sweden)
• Yusuf Menda (University of Iowa, USA)
• Elcin Zan (NYU Langone Medical Center, USA)
• Emily Bergsland (University of California, San Francisco, USA)
• Andreas Kjaer (Copenhagen University Hospital, Denmark)
• Lauren Fishbein (University of Colorado Anschutz Medical Campus, USA)
• Daniel Pryma (University of Pennsylvania, USA)
• David Bushnell (University of Iowa, USA)
• Andrei Iagaru (Stanford University, USA)
• Josh Mailman (NorCal NET Support Group, USA).  Josh will present on “”Patient Perspective on Sequencing Therapies.”

For the meeting agenda and further information, CLICK HERE.